Navigation Links
Genoptix Announces Participation at the BIOCOM Investor Conference 2008
Date:10/22/2008

CARLSBAD, Calif., Oct. 22 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today announced the Company's participation at the BIOCOM Investor Conference 2008 scheduled to take place at the Hyatt Regency in La Jolla, CA on October 26-28, 2008.

Dr. Tina Nova, President and CEO of Genoptix, will present at the conference on Monday, October 27, beginning at approximately 9:30 a.m. PDT. Dr. Nova will provide an overview of the Company's specialized diagnostic laboratory service offerings, growth strategies and past operational performance.

The presentation is expected to last approximately 20 minutes, followed by a 5 minute question and answer session. The presentation will be webcast live and made accessible through the investor relations section of the Genoptix website at http://www.genoptix.com. Those who would like to listen to the presentation should go to this site at least 15 minutes prior to the event to register, download and install any necessary software. A replay will also be available for 30 days following the initial presentation web cast.

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community- based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.

Forward-Looking Statements

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements. Genoptix disclaims, however, any intent or obligation to update these forward-looking statements.


'/>"/>
SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genoptix Announces Participation at the UBS Global Life Sciences Conference
2. Genoptix Reports Strong Financial Results For Third Quarter 2007
3. Medivation Announces Expiration of Hart-Scott-Rodino Waiting Period for Collaboration With Pfizer
4. Medivation Announces Presentation of 24-Week Clinical Data of MDV3100 in Castration-Resistant Prostate Cancer Patients
5. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
6. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
8. Boston Scientific Announces Results for Third Quarter Ended September 30, 2008
9. Advanced Life Sciences Announces Presentations at Fall Scientific and Investor Conferences and Third Quarter 2008 Earnings Conference Call
10. NxStage Announces Streamline(TM) Blood Tubing Set Supply Agreement with Renal Advantage Inc.
11. BioElectronics Announces Significant Progress in Canadian and International Distribution
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... NY (PRWEB) , ... May 03, 2016 , ... According ... Hospital , for definitive prostate cancer treatment, patients traditionally had two main treatment options: ... treatment plan would be made. , New technology has enabled doctors to administer ...
(Date:5/2/2016)... , ... May 02, 2016 , ... StarNet Communications Corp, ... announced the addition of three Secure Remote Desktop modules to its flagship X-Win32 PC ... from Linux and Unix servers to the user’s PC over encrypted SSH. , Traditionally, ...
(Date:4/29/2016)... ... April 29, 2016 , ... Amendia, Inc., a ... procedures, today announced the completion of a significant transaction and partnership that positions ... customers and partners. Kohlberg & Company, L.L.C. (“Kohlberg”), a leading private equity ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced today ... via 510(k) for sale in the United States. These components expand the capabilities ... With one-level sales beginning in October of 2015, the company has seen significant ...
Breaking Biology Technology:
(Date:3/11/2016)... -- --> --> ... Market by Technology (Pattern Recognition), by Component (Hardware, Software, ... (On-Premises and Cloud), by Industry Vertical and by Region ... global market is expected to grow from USD 12.49 ... at a CAGR of 19.1%. , ...
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
(Date:3/8/2016)...   Valencell , the leading innovator in ... secured $11M in Series D financing. The investment ... fund being launched by UAE-based financial services company ... TDF Ventures and WSJ Joshua Fund. Valencell plans ... growth and accelerate its pioneering innovation in accurate ...
Breaking Biology News(10 mins):